SLN

Silence Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 0/10
  • Value↓ 0/10
Silence Therapeutics sales and earnings growth
SLN Growth
Low
  • Revenue Y/Y↓ -98.71%
  • EPS Y/Y↓ -90.91%
  • FCF Y/Y↑ 8.14%
Silence Therapeutics gross and profit margin trends
SLN Profitability
Low
  • Gross margin ↑ 61.50%
  • EPS margin↓ -15851.90%
  • ROIC 5Y↓ -137.33%
Silence Therapeutics net debt vs free cash flow
SLN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Silence Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗